Hydrocodone extended release - Egalet

Drug Profile

Hydrocodone extended release - Egalet

Alternative Names: Abuse-deterrent extended-release hydrocodone - Egalet; AD ER hydrocodone - Egalet; Egalet-004; S 718632

Latest Information Update: 12 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Egalet
  • Developer Egalet; Shionogi
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 05 Jun 2017 Egalet has patent protection for Guardian Technology in USA
  • 23 Mar 2017 Egalet has patent protection for Guardian™ Technology in Europe, Australia and Canada
  • 11 Mar 2016 Egalet Corporation completes a phase I trial in Pain in USA prior to March 2016 (Egalet Corporation 10-K; March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top